Close

Clover Biopharmaceuticals' COVID-19 Vaccine with Dynavax's (DVAX) CpG 1018 Adjuvant Meets All Endpoints in Phase 2/3 Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. GM
2. SPY
3. TSLA
4. CPRI
5. NVDA
6. ADBE
7. VERX
8. RIL:IN
9. MTTR
10. TPR


Go back to Clover Biopharmaceuticals' COVID-19 Vaccine with Dynavax's (DVAX) CpG 1018 Adjuvant Meets All Endpoints in Phase 2/3 Trial

COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial

September 22, 2021 7:08 AM EDT

EMERYVILLE, Calif., Sept. 22, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Clover Biopharmaceuticals (Clover) reported positive data for their protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum) adjuvanted with Dynavax's CpG 1018 adjuvant, which achieved the primary and secondary efficacy endpoints in SPECTRA, a global pivotal Phase 2/3 clinical trial... More